GlassScriptPhysician profile
Nadya Ajanee
NPI 1639284276
$12,171.93
in general payments reported to CMS, 2019-2025
47 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $1,472 · 2021: $1,802 · 2022: $1,927 · 2023: $2,175 · 2024: $1,683 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,886.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,151.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,426.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,344.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,279.31 | 2019-2025 | Repatha, Repatha, Evenity |
| Abbvie INC. | $1,044.43 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $733.28 | 2019-2025 | |
| Glaxosmithkline, LLC. | $493.38 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $356.16 | 2019-2025 | |
| Esperion Therapeutics, INC. | $310.02 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $305.62 | 2022-2025 | |
| Abbott Laboratories | $288.18 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.40 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.53 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $167.89 | 2019-2021 | |
| Exact Sciences Corporation | $151.96 | 2023-2025 | Cologuard Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadya Ajanee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.